omacetaxine
Selected indexed studies
- Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia. (Expert Rev Hematol, 2016) [PMID:26853281]
- Omacetaxine mepesuccinate in chronic myeloid leukemia. (Expert Opin Pharmacother, 2014) [PMID:25301179]
- Homoharringtonine and omacetaxine for myeloid hematological malignancies. (J Hematol Oncol, 2014) [PMID:24387717]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia. (2016) pubmed
- Omacetaxine mepesuccinate in chronic myeloid leukemia. (2014) pubmed
- Homoharringtonine and omacetaxine for myeloid hematological malignancies. (2014) pubmed
- Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma. (2021) pubmed
- Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia. (2013) pubmed
- Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. (2009) pubmed
- Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia. (2014) pubmed
- Omacetaxine as an anticancer therapeutic: what is old is new again. (2011) pubmed
- Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval. (2013) pubmed
- Homoharringtonine (omacetaxine mepesuccinate) limits the angiogenic capacity of endothelial cells and reorganises filamentous actin. (2025) pubmed